<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303572</url>
  </required_header>
  <id_info>
    <org_study_id>PRO19070080</org_study_id>
    <secondary_id>H30MC24050</secondary_id>
    <nct_id>NCT04303572</nct_id>
  </id_info>
  <brief_title>The Hemophilia Inhibitor Eradication Trial</brief_title>
  <official_title>Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Margaret Ragni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Resources and Services Administration (HRSA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center randomized phase III clinical trial, the Inhibitor Eradication Trial,&#xD;
      in which Eloctate ITI plus Emicizumab will be compared with Eloctate ITI alone to eradicate&#xD;
      inhibitors in severe hemophilia A.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center randomized phase III clinical trial, the Inhibitor Eradication Trial,&#xD;
      in which Eloctate ITI plus Emicizumab will be compared with Eloctate ITI alone to eradicate&#xD;
      inhibitors in patients with severe hemophilia A This adaptive design is necessary as&#xD;
      randomized trials in rare diseases are often not possible. The INHIBIT Clinical Trials&#xD;
      Platform includes two linked trials, the Inhibitor Prevention Trial (Prevention Trial) and&#xD;
      the Inhibitor Eradication Trial (Eradication Trial) that will be conducted at up to 41 U.S.&#xD;
      hemophilia treatment centers (HTCs) affiliated with universities. The Inhibitor Eradication&#xD;
      Trial is a 48-week randomized phase III trial, in which 90 previously treated patients (PTPs)&#xD;
      with severe hemophilia A and high-responding inhibitors (anti-VIII &gt; 0.6 B.U.), will be&#xD;
      enrolled. Subjects will include individuals with severe hemophilia A who develop inhibitors&#xD;
      during the linked Inhibitor Prevention Trial and adults or children at the same HTCs&#xD;
      refractory to or never undergoing immune tolerance induction (ITI). Once enrolled, subjects&#xD;
      who meet all the inclusion and none of the exclusion criteria, will be randomized to weekly&#xD;
      Eloctate ITI plus weekly Emicizumab vs. weekly Eloctate ITI alone to eradicate inhibitor&#xD;
      formation, defined as anti-FVIII&lt;0.6 B.U. Blood draws will be minimized to 6 timepoints, pre,&#xD;
      4, 12, 24, 36, and 48 weeks, and validated for small volumes, 3.8 cc (Â¾ tsp) each. The&#xD;
      Inhibitor Eradication Trial is considered greater than minimal risk as study drug is given&#xD;
      before the first bleed and special inhibitor studies are obtained. (NB: The Inhibitor&#xD;
      Eradication Trial (PRO19070080) is linked to the Inhibitor Prevention Trial (PRO19040140), as&#xD;
      part of the INHIBIT Clinical Trials Platform, and both trials will be conducted efficiently&#xD;
      in the same hemophilia treatment centers (HTCs), with the same MDs, coordinators, visit&#xD;
      frequency, blood sampling, and assays.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">August 2027</completion_date>
  <primary_completion_date type="Anticipated">August 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase III open-label, randomized controlled trial comparing immune tolerance induction with one drug, with or without a second drug in the eradication of hemophilia inhibitors.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibitor eradication</measure>
    <time_frame>48 weeks</time_frame>
    <description>The proportion eradicating anti-FVIII inhibitors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>48 weeks</time_frame>
    <description>The number of bleeding events: hematoma, joint, central nervous system, other bleeds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVIII trough level</measure>
    <time_frame>48 weeks</time_frame>
    <description>The FVIII trough activity by chromogenic assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human leukocyte antigen (HLA) haplotype</measure>
    <time_frame>48 weeks</time_frame>
    <description>The number of HLA haplotype variants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVIII mutation</measure>
    <time_frame>48 weeks</time_frame>
    <description>The number of FVIII mutation variants.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <arm_group>
    <arm_group_label>Eloctate ITI plus Emicizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Eloctate 100 IU/kg every other day by intravenous infusion plus Emicizumab 1.5 mg/kg subcutaneously (following 3 mg/kg/wk x 4 induction) in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eloctate ITI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B: Eloctate 100 IU/kg every other day by intravenous infusion in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eloctate ITI</intervention_name>
    <description>This is a factor VIII-Fc infusion protein.</description>
    <arm_group_label>Eloctate ITI</arm_group_label>
    <arm_group_label>Eloctate ITI plus Emicizumab</arm_group_label>
    <other_name>rFVIIIFc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emicizumab</intervention_name>
    <description>This is a bispecific monoclonal antibody FVIII mimic.</description>
    <arm_group_label>Eloctate ITI plus Emicizumab</arm_group_label>
    <other_name>Hemlibra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male adults or children &gt; 4 months of age.&#xD;
&#xD;
          2. Severe hemophilia A (FVIII &lt; 0.01 U/ml).&#xD;
&#xD;
          3. Current or past high-responding inhibitor, anti-FVIII &gt;= 5.0 B.U., ITI-refractory or&#xD;
             ITI-naive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acquired hemophilia or any bleeding disorder other than hemophilia A.&#xD;
&#xD;
          2. Current use of Emicizumab, or if used, &gt; 8 weeks since last treatment.&#xD;
&#xD;
          3. Use of an experimental drug(s).&#xD;
&#xD;
          4. Surgery anticipated in the next 48 weeks.&#xD;
&#xD;
          5. Life expectancy less than 5 years.&#xD;
&#xD;
          6. Patient/parent/caretaker unable or unwilling to keep a personal diary of bleeding&#xD;
             frequency and study drug treatment, make monthly visits and blood draws at weeks 4, 8,&#xD;
             12, 24, 36, and 48.&#xD;
&#xD;
          7. Other illness, condition, or reason in the opinion of the investigator that would make&#xD;
             the patient unsuitable for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret V Ragni, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret V Ragni, MD, MPH</last_name>
    <phone>412-209-7288</phone>
    <email>ragni@pitt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Ivanco</last_name>
    <phone>412-209-7425</phone>
    <email>des2@pitt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hemophilia Center of Western PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Ragni, MD MPH</last_name>
      <phone>412-209-7288</phone>
      <email>ragni@pitt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Vehec, MSN RN</last_name>
      <phone>412-209-7645</phone>
      <email>dvehec@pitt.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh and Hemophilia Center Western PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dana Ivanco</last_name>
      <phone>412-209-7425</phone>
      <email>des2@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Margaret V Ragni, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig Seaman, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederico Xavier, MD MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ragni MV, George LA; Members of Working Group 1, the NHLBI State of the Science Workshop on factor VIII inhibitors: Generating a national blueprint for future research. The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors. Haemophilia. 2019 Jul;25(4):581-589. doi: 10.1111/hae.13717.</citation>
    <PMID>31329364</PMID>
  </reference>
  <reference>
    <citation>Ebbert PT, Xavier F, Malec LM, Seaman CD, Ragni MV. Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A. Thromb Res. 2020 Nov;195:51-54. doi: 10.1016/j.thromres.2020.07.004. Epub 2020 Jul 5.</citation>
    <PMID>32653601</PMID>
  </reference>
  <reference>
    <citation>Bertolet M, Brooks MM, Ragni MV. The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia. Blood Adv. 2020 Nov 10;4(21):5433-5441. doi: 10.1182/bloodadvances.2020002789.</citation>
    <PMID>33156923</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Margaret Ragni</investigator_full_name>
    <investigator_title>Professor of Medicine and Clinical and Translational Research</investigator_title>
  </responsible_party>
  <keyword>hemophilia</keyword>
  <keyword>inhibitor formation</keyword>
  <keyword>Eloctate</keyword>
  <keyword>Emicizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A biologic specimen and data repository for this trial will be available at the Graduate School of Public Health (GSPH) Data Center repository for investigators who make formal application request and is formally approved by the Coordinating Center (Pitt) and Data Center (GSPH).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within one year of trial completion.</ipd_time_frame>
    <ipd_access_criteria>Access will be determined by the Study Team.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

